Oxyrane (Netherlands) a clinical-stage biopharmaceutical focused on enzyme replacement therapies for Pompe’s a lysosomal storage disease, closed a $26.5M Series D financing. Participants include Forbion Capital Partners, Morningside Group and New Science Ventures.

Biocartis (Switzerland) a commercial-stage molecular diagnostics company focused on rapid biomarker identification, closed a $100M Series C financing. Participants include Debiopharm Group, Philips, Johnson & Johnson Development Corp, Wellcome Trust, Korys and Valiance.

NuCana BioMed (United Kingdom) a preclinical-stage pharmaceutical company focused oncology, closed a $10.4M Series A financing. Participants include Sofinnova Partners, Morningside Ventures, Scottish Venture Fund and Alida Capital International.

Pixeon (Brazil) a commercial-stage medical imaging software company focused on image processing and management, closed a $25M Series C financing. Participants include Intel Capital.

Avraham Pharmaceuticals (Israel) a clinical-stage small molecule company focused on the treatment of Alzheimer’s, closed a $3M Series B financing. Participants include Yissum Research Development Foundation, Cial Biotechnology Industries and Technion Research and Development Foundation.

Verona Pharma (United Kingdom) a clinical-stage biotechnology company focused on chronic respiratory diseases and inflammation for asthma, COPD, cough, and rhinitis, closed a $11.5M Series A financing. Participants include Henderson Global Investors.

TopiVert (United Kingdom) a development-stage pharmaceutical company focused on topical medicines for inflammatory diseases of the eye and gut, closed a $12.5M Series A financing. Participants include Imperial Innovations Group and SV Life Sciences.

MedLumics (Spain) a development-stage diagnostic device company focused on optical coherence tomography imaging for ophthalmology and intravascular imaging in cardiology, dermatology and dentistry, closed a $3.25M Series A financing. Participants include Ysios Capital Partners and Caixa Capital.

Atox Bio (Israel) a clinical-stage biotechnology company focused on small molecules for the treatment of severe bacterial infections, sepsis, necrotizing soft tissue infections and intra-abdominal infections, closed a $3.25M Series A financing. Participants include Esperante.

Cytoo (Grenoble, FRA) a commercial-stage medical device company focused on cell based assays, high content analysis and cell screening, closed a $10M Series C financing. Participants include Sham, Entrepreneurs Fund and Auriga Ventures.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

PolyTherics (United Kingdom) a preclinical-stage biochemistry company focused on pegylation technologies, closed a $3.5M Series C financing. Participants include Beringea, Imperial Innovation and The Capital Fund.
Thanx for your patience as we catch-up.

Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $3.5M Series B financing. Participants include Parinvest Capital, La Financiere Gaspard and Truffle Capital
Thanx for your patience as we catch-up.